SDMHF:OTO-Sartorius Stedim Biotech (USD)

COMMON STOCK | Medical Instruments & Supplies | OTC Pink

Last Closing

USD 224.44

Change

0.00 (0.00)%

Market Cap

USD 5.95B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Sartorius Stedim Biotech SA is a pharmaceutical and laboratory equipment supplier. It provides equipment and services for the development, quality assurance and production processes for the biopharmaceutical industry.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-28 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOY Essilor International SA

-0.58 (-0.50%)

USD 109.05B
ESLOF EssilorLuxottica Société ano..

-1.38 (-0.60%)

USD 107.93B
HOCPF HOYA Corporation

N/A

USD 48.46B
HOCPY Hoya Corp

+2.25 (+1.71%)

USD 45.95B
CLPBF Coloplast A/S

N/A

USD 29.48B
CLPBY Coloplast A

-0.28 (-2.14%)

USD 29.48B
TRUMF Terumo Corporation

+0.11 (+0.60%)

USD 28.34B
SAUHF Straumann Holding AG

-3.14 (-2.38%)

USD 24.34B
OCPNF Olympus Corporation

N/A

USD 21.42B
SRTOY Sartorius Stedim Biotech S.A

N/A

USD 20.59B

ETFs Containing SDMHF

RNDM 1.76 % 0.65 %

N/A

N/A
SCIX 1.04 % 0.38 %

N/A

N/A
KIE SPDR® S&P Insurance ETF 0.00 % 0.35 %

+0.28 (+-0.63%)

N/A
DJMC:LSE iShares EURO STOXX Mid UC.. 0.00 % 0.00 %

-35.00 (-0.63%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.90% 35% F 30% F
Dividend Return 0.28% 23% F 6% D-
Total Return -14.62% 32% F 29% F
Trailing 12 Months  
Capital Gain -15.66% 59% D- 47% F
Dividend Return 0.28% 17% F 4% F
Total Return -15.38% 54% F 46% F
Trailing 5 Years  
Capital Gain 82.69% 92% A 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 82.69% 84% B 85% B
Average Annual (5 Year Horizon)  
Capital Gain 27.86% 77% C+ 70% C-
Dividend Return 28.10% 75% C 68% D+
Total Return 0.24% 20% F 8% B-
Risk Return Profile  
Volatility (Standard Deviation) 64.89% 39% F 42% F
Risk Adjusted Return 43.31% 83% B 82% B
Market Capitalization 5.95B 83% B 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.